EHR to EDC
Next-generation innovation transforming unstructured EHR data into usable data for clinical trials
Due to technology barriers, unstructured patient data from EHR systems has long been an untapped resource for clinical research. With TrialKit AI, research teams now have direct access to this data, with little to no disruption to existing workflows. TrialKit AI parses unstructured data from any EHR platform and populates it as clean, structured data into the TrialKit data collection and study management platform (or any other structured database).
Alleviate painful data-related bottlenecks in clinical trials
TrialKit AI utilizes Crucial Data Solutions’ proprietary machine-learning API, first-of-its-kind technology, that finally makes EHR to EDC interoperability a reality in the clinical research space. Simply put, it serves as middleware that connects any EHR system data to the structured database you use for your clinical trials — without the need to map fields from the EHR platform.
This new technological breakthrough is very disruptive in a good way.
TrialKit AI may be used in conjunction with the TrialKit data collection and study management platform or as a standalone tool with other database platforms. And, there are no intensive integrations necessary. Leverage TrialKit AI’s lightweight API and avoid having to directly integrate with EHR systems.
- Ensures a 21 CFR Part 11 and HIPAA compliant environment
- Remains secure and compliant, by anonymizing patient data from EHR documents
- Eliminates manual transcription and double data entry, saving weeks of source data verification
- Saves time and resources with automatic data entry
- Minimizes error rates
- Expedites data verification and cleaning by at least tenfold
“This solution specifically addresses both the vision outlined in the 21st Century Cures Act for EHR-EDC interoperability and the US FDA’s interest in industry working together to fix this problem. It also allows us to finally step through the front door to the next frontier in research where research costs to sponsors can be dramatically reduced, time to market is improved, and patient access to new therapies is faster.”
— Alethea Wieland, Founder and President, Clinical Research Strategies
